Longmore J, Razzaque Z, Shaw D, Davenport A P, Maguire J, Pickard J D, Schofield W N, Hill R G
Merck Sharp & Dohme Research Laboratories, Neuroscience Research Centre, Eastwick Road, Harlow, Essex, UK.
Br J Clin Pharmacol. 1998 Dec;46(6):577-82. doi: 10.1046/j.1365-2125.1998.00821.x.
We compared the vasoconstrictor effects of 5-HT with those of the selective 5-HT1B/1D-receptor agonists sumatriptan and rizatriptan in human isolated cranial (middle meningeal) arteries. In addition selective 5-HT1B- or 5-HT1D-receptor antibodies were used in combination with semiquantitative immunohistochemical techniques to compare the levels of expression of these receptors in human middle meningeal and coronary arteries.
Middle meningeal and coronary arteries were obtained (with consent) from either neurosurgical patients or donor hearts, respectively. Segments of middle meningeal artery were mounted in organ baths for isometric recording and cumulative concentration-effect curves to 5-HT, rizatriptan and sumatriptan were obtained. Frozen fresh sections of middle meningeal and coronary arteries were subjected to standard immunohistochemical techniques using specific 5-HT1B- or 5-HT1D-receptor primary antibodies and a radiolabelled secondary antibody. Data were subjected to analysis of variance (ANOVA) and nonlinear regression analysis.
5-HT, rizatriptan and sumatriptan were potent vasoconstrictors in human isolated middle meningeal artery (EC50 values=32, 90 and 71 nM, respectively). A significantly higher level of 5-HT1B-receptor immunoreactivity was detected in middle meningeal artery compared with coronary artery (ANOVA, F=7.95, DF=1,4, P<0.05).
Rizatriptan and sumatriptan act selectively to cause vasoconstriction in human isolated middle meningeal artery and are 10-fold more potent than in human coronary artery. The higher level of expression of 5-HT1B-receptors in middle meningeal compared with coronary artery provides a pharmacological basis for the craniovascular selectively of both rizatriptan and sumatriptan.
我们比较了5-羟色胺(5-HT)与选择性5-HT1B/1D受体激动剂舒马曲坦和利扎曲坦对人离体颅(脑膜中)动脉的血管收缩作用。此外,使用选择性5-HT1B或5-HT1D受体抗体结合半定量免疫组织化学技术,比较这些受体在人脑膜中动脉和冠状动脉中的表达水平。
分别从神经外科手术患者或供体心脏获取(经同意)脑膜中动脉和冠状动脉。将脑膜中动脉段安装在器官浴槽中进行等长记录,并获得5-HT、利扎曲坦和舒马曲坦的累积浓度-效应曲线。使用特异性5-HT1B或5-HT1D受体一抗和放射性标记二抗,对脑膜中动脉和冠状动脉的新鲜冰冻切片进行标准免疫组织化学技术处理。数据进行方差分析(ANOVA)和非线性回归分析。
5-HT、利扎曲坦和舒马曲坦在人离体脑膜中动脉中是强效血管收缩剂(EC50值分别为32、90和71 nM)。与冠状动脉相比,脑膜中动脉中检测到的5-HT1B受体免疫反应性水平显著更高(ANOVA,F = 7.95,DF = 1,4,P < 0.05)。
利扎曲坦和舒马曲坦在人离体脑膜中动脉中选择性地引起血管收缩,其效力比在人冠状动脉中强10倍。与冠状动脉相比,脑膜中动脉中5-HT1B受体的较高表达水平为利扎曲坦和舒马曲坦的颅血管选择性提供了药理学基础。